Procarbazine (DB01168): A Comprehensive Pharmacological and Clinical Monograph

Introduction and Overview

Procarbazine is a potent antineoplastic agent belonging to the methylhydrazine class of drugs.[1] It functions as a cell cycle phase-nonspecific prodrug that, following metabolic activation, exerts its primary cytotoxic effects as a DNA alkylating agent.[3] Historically, Procarbazine holds a landmark position in the field of oncology. It was an integral component of the MOPP (mechlorethamine, Oncovin® [vincristine], procarbazine, prednisone) regimen, which in the 1960s became one of the first combination chemotherapy protocols to demonstrate the potential to cure a disseminated cancer—advanced-stage Hodgkin's disease.[3] This breakthrough established a new paradigm in cancer treatment, proving that systemic, metastatic malignancies could be effectively eradicated with combination drug therapy.

The pharmacological profile of Procarbazine is uniquely complex, a direct consequence of its developmental origins. The drug was not initially designed as a cancer therapeutic but emerged from a research program screening hydrazine derivatives for monoamine oxidase (MAO) inhibitory activity.[8] Its antineoplastic properties were discovered serendipitously during this process. This dual heritage—a potent cytotoxic agent fused with a neurologically active MAO inhibitor—is the central characteristic that defines its clinical use and its significant safety concerns. The residual MAO inhibitory activity is not a minor off-target effect but a core feature that dictates a stringent set of dietary and drug-related precautions to prevent potentially fatal interactions.[2]

Clinically, Procarbazine's primary FDA-approved indication remains for the treatment of Stage III and IV Hodgkin's lymphoma, typically as part of a combination regimen.[11] Beyond this, it has found a critical off-label role in neuro-oncology for the treatment of malignant brain tumors, such as glioblastoma and anaplastic gliomas, a use supported by its ability to penetrate the central nervous system.[3]

The efficacy of Procarbazine is counterbalanced by a significant toxicity profile. It is a high-risk medication known to cause severe myelosuppression, profound neurotoxicity, and substantial long-term risks, including secondary malignancies and irreversible infertility.[3] Consequently, its administration is restricted to physicians experienced in the use of potent chemotherapeutic agents and conducted in specialized clinical settings equipped for intensive patient monitoring.[13]

Physicochemical Properties and Formulations

Chemical Identity and Structure

Procarbazine is chemically classified as a benzamide, specifically a derivative of methylhydrazine.[1] It is formed by the formal condensation of the carboxylic acid group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine.[6] For clinical and pharmaceutical purposes, the drug is formulated as its hydrochloride salt, Procarbazine Hydrochloride, to enhance its stability and solubility.[6] This distinction between the parent base and its salt form is critical for accurate chemical and pharmaceutical characterization. The fundamental properties and identifiers for both forms are detailed in Table 1.

Table 1: Chemical and Physical Identifiers for Procarbazine and Procarbazine Hydrochloride

Property	Procarbazine (Base)	Procarbazine Hydrochloride (Salt)
IUPAC Name	4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide 6	4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide;hydrochloride 16
Common Names	Procarbazine 3	Procarbazine HCl, Ibenzmethyzine hydrochloride 4
DrugBank ID	DB01168 3	DB01168 (Parent)
CAS Number	671-16-9 3	366-70-1 6
Molecular Formula	C12​H19​N3​O 3	C12​H20​ClN3​O 16
Molecular Weight	221.30 g/mol 6	257.76 g/mol 6
UNII	35S93Y190K 3	XH0NPH5ZX8 16
InChI	InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16) 3	InChI=1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H 16
InChIKey	CPTBDICYNRMXFX-UHFFFAOYSA-N 3	DERJYEZSLHIUKF-UHFFFAOYSA-N 16
SMILES	CC(C)NC(=O)C1=CC=C(C=C1)CNNC 6	CC(C)NC(=O)C1=CC=C(C=C1)CNNC.Cl 16

Physical Properties and Formulation Rationale

Procarbazine hydrochloride presents as a white to pale yellow crystalline powder, characterized by a slight odor and a bitter taste.[6] Its solubility profile is a key aspect of its formulation. The hydrochloride salt is soluble in water (approximately 1 g in 7 mL), alcohol, and methanol, but shows poor solubility in ether and chloroform.[6] A critical property is its instability in neutral or alkaline aqueous solutions; its stability is significantly greater in acidic environments.[6]

The selection of the hydrochloride salt form for the final drug product is a deliberate pharmaceutical development choice driven by these physicochemical properties. The salt form confers superior crystallinity, stability, and aqueous solubility compared to the parent base, which are essential characteristics for manufacturing a consistent and bioavailable oral dosage form. The enhanced stability in an acidic state also aligns with the environment of the stomach, facilitating dissolution upon oral administration.

Commercial Formulations and Brand Names

Procarbazine is commercially available as an oral formulation, typically supplied in 50 mg capsules.[5] These capsules contain Procarbazine Hydrochloride as the active pharmaceutical ingredient, along with inactive excipients such as cornstarch, mannitol, and talc, which aid in the manufacturing process and product stability.[20]

The drug is marketed under several brand names globally:

• United States and Canada: The primary brand name is Matulane®.[3]
• International Markets: Common foreign brand names include Natulan® and Natulanar®.[3]

For historical and research purposes, it is also identified by a number of synonyms and code names, including ibenzmethyzin hydrochloride, PCB, PCZ, and the developmental codes Ro 4-6467/1 and NSC-77213.[4]

Pharmacology

3.1 Mechanism of Action

The precise cytotoxic mechanism of Procarbazine has not been fully elucidated but is understood to be a complex, multifactorial process initiated by metabolic activation.[2] Procarbazine is a prodrug that requires biotransformation to exert its antineoplastic effects. This activation occurs primarily in the liver, involving both the cytochrome P450 (CYP) microsomal enzyme system and mitochondrial monoamine oxidase.[1]

This metabolic conversion results in a cascade of events, generating a "cocktail" of highly reactive chemical species that launch a multi-pronged attack on cancer cells. This complex assault likely explains the drug's high potency and its lack of cross-resistance with some other conventional alkylating agents.[2] The key downstream cytotoxic mechanisms include:

1. DNA Alkylation and Methylation: The primary active metabolites, including azo- and azoxy-derivatives, function as alkylating agents. They covalently attach methyl groups to nucleic acids, with a preference for the O6 and N7 positions of guanine residues within the DNA strand.[1] This chemical modification disrupts the normal structure and function of DNA, interfering with replication and transcription.
2. DNA Damage via Oxidative Stress: The auto-oxidation of Procarbazine during its metabolism generates hydrogen peroxide (H2​O2​) and other reactive oxygen species (free radicals).[2] These molecules directly attack and damage the DNA backbone, causing single- and double-strand breaks. This mode of action produces a biological effect akin to that of ionizing radiation.[9]
3. Inhibition of Macromolecular Synthesis: Procarbazine and its metabolites broadly inhibit the synthesis of DNA, RNA, and protein, effectively shutting down the cell's core operational machinery.[2] One proposed pathway for this effect is the inhibition of the transmethylation of methionine into transfer RNA (tRNA).[1] The resulting lack of functional tRNA halts protein synthesis, which in turn leads to the cessation of DNA and RNA synthesis.[13]

In addition to its cytotoxic effects, Procarbazine retains the pharmacological property of its parent class, acting as a weak, non-selective monoamine oxidase (MAO) inhibitor.[2] This MAO inhibition is not believed to contribute to its anticancer activity but is the direct cause of its most dangerous drug-food and drug-drug interactions.[27]

3.2 Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion)

Procarbazine's journey through the body is characterized by rapid absorption, extensive metabolism, and clearance. Its key pharmacokinetic (PK) parameters are summarized in Table 2.

Table 2: Key Pharmacokinetic Parameters of Procarbazine

Parameter	Value / Description	Source(s)
Oral Absorption	Rapid and nearly complete	1
Time to Peak (Tmax)	~1 hour	1
Plasma Half-life (T½)	~10 minutes (parent drug)	3
Distribution	Rapid and wide; readily crosses the blood-brain barrier	2
Metabolism	Extensive hepatic and renal metabolism via CYP450 and MAO	2
Primary Metabolites	Active: Azo- and azoxy-derivatives, H2​O2​. Inactive: N-isopropylterephthalamic acid	2
Excretion	Primarily renal (25-70% in 24 hours), mainly as metabolites; <5% as unchanged drug	1

Absorption: Following oral administration, Procarbazine is absorbed rapidly and almost completely from the gastrointestinal tract, with peak plasma concentrations achieved within approximately one hour.[1]

Distribution: The drug is distributed quickly and widely throughout the body, with notable concentrations in the liver, kidneys, and skin.[2] A crucial pharmacokinetic property, particularly for its use in neuro-oncology, is its ability to readily cross the blood-brain barrier and achieve therapeutic concentrations in the cerebrospinal fluid.[2]

Metabolism: Procarbazine undergoes extensive and complex metabolism, primarily in the liver but also in the kidneys.[3] The metabolic pathways involve auto-oxidation and enzymatic transformation by both the cytochrome P450 system and mitochondrial MAO.[1] This process generates the active cytotoxic species previously described, while the major inactive metabolite, N-isopropylterephthalamic acid, is formed for excretion.[2]

A sophisticated pharmacokinetic phenomenon observed with Procarbazine is the autoinhibition of its own metabolism. A clinical study in patients with glioma demonstrated that peak plasma concentrations of the drug were markedly higher on day 5 of a daily dosing schedule compared to day 1, an effect that could not be attributed to simple drug accumulation.[29] This suggests that Procarbazine or its metabolites inhibit the hepatic enzymes responsible for its clearance over several days of continuous administration. This non-linear pharmacokinetic behavior provides a compelling rationale for the common clinical practice of initiating therapy with a lower, escalating dose for the first week.[30] This "starter dose" allows the body to acclimate before the autoinhibition mechanism leads to significantly higher drug exposure and a greater potential for toxicity later in the treatment cycle.

Excretion: The elimination of Procarbazine is primarily through the kidneys. Between 25% and 70% of the administered dose is excreted in the urine within the first 24 hours, overwhelmingly in the form of metabolites.[1] Less than 5% of the parent drug is excreted unchanged.[1] The plasma half-life of the parent compound is remarkably short, at approximately 10 minutes, though the biological effects may be more prolonged due to the activity of its longer-lasting metabolites.[2]

Clinical Applications and Efficacy

4.1 FDA-Approved and Off-Label Indications

Procarbazine's clinical utility is well-defined, with one primary approved indication and several critical off-label uses.

• FDA-Approved Indication: The U.S. Food and Drug Administration (FDA) has approved Procarbazine, for use in combination with other anticancer drugs, for the palliative treatment of Stage III and IV Hodgkin's lymphoma.[11] This remains its sole officially approved indication.
• Established Off-Label Uses:
• Malignant Brain Tumors: Procarbazine is a cornerstone agent in neuro-oncology. It is widely used in combination regimens to treat high-grade malignant gliomas, including glioblastoma multiforme, anaplastic astrocytoma, and anaplastic oligodendroglioma.[1] This application is so well-established that on August 8, 2006, the FDA granted Procarbazine an Orphan Drug Designation for the "Treatment of malignant glioma," acknowledging its importance for this rare disease population despite it not being a formally approved indication.[15]
• Non-Hodgkin's Lymphoma: Although less common than in Hodgkin's lymphoma, Procarbazine is incorporated into certain chemotherapy protocols for various types of non-Hodgkin's lymphoma.[1]

4.2 Role in Combination Chemotherapy Regimens

Due to the rapid development of therapeutic resistance when used as monotherapy, Procarbazine is almost exclusively administered as part of a multi-agent combination chemotherapy regimen.[1] It has been a key component of several landmark and contemporary protocols, as detailed in Table 3.

Table 3: Key Combination Chemotherapy Regimens Featuring Procarbazine

Regimen Acronym	Full Name	Component Drugs	Typical Indication(s)	Typical Cycle Length
MOPP	Mechlorethamine, Oncovin® (vincristine), Procarbazine, Prednisone	Mechlorethamine, Vincristine, Procarbazine, Prednisone	Hodgkin's lymphoma (historically)	28 days
BEACOPP (Standard)	Bleomycin, Etoposide, Adriamycin® (doxorubicin), Cyclophosphamide, Oncovin® (vincristine), Procarbazine, Prednisone	Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone	Advanced-stage Hodgkin's lymphoma	21 days
Escalated BEACOPP	(Same as above, with higher doses of specific agents)	Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, G-CSF support	High-risk, advanced-stage Hodgkin's lymphoma	21 days
PCV	Procarbazine, CCNU (lomustine), Vincristine	Procarbazine, Lomustine, Vincristine	Malignant gliomas (e.g., glioblastoma, anaplastic oligodendroglioma)	6-8 weeks

Sources: [1]

MOPP Regimen: The MOPP protocol represents a pivotal moment in medical history, being the first combination regimen to reliably cure advanced Hodgkin's disease.[3] While its introduction was revolutionary, MOPP has been largely supplanted in the first-line setting by regimens like ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), which offer a more favorable long-term toxicity profile, particularly with lower risks of secondary leukemia and infertility.[3]

BEACOPP Regimen: The clinical role of Procarbazine in Hodgkin's lymphoma has evolved from a standard component in MOPP to a part of the more specialized, high-intensity BEACOPP regimen. Developed by the German Hodgkin's Lymphoma Study Group, BEACOPP was designed to improve cure rates in patients with advanced-stage, high-risk disease through dose intensification and the addition of etoposide.[36] Clinical trials have shown that BEACOPP is more effective than standard COPP/ABVD at controlling the disease but at the cost of increased acute hematologic toxicity.[36] This illustrates the ongoing clinical balance between maximizing efficacy and minimizing toxicity. Procarbazine's inclusion in BEACOPP underscores its continued relevance as a potent agent reserved for situations where maximum therapeutic intensity is required. Within the BEACOPP protocol, Procarbazine is typically administered at a dose of 100 mg/m² daily for the first 7 days of each cycle.[21]

PCV Regimen: In the treatment of malignant brain tumors, Procarbazine's ability to cross the blood-brain barrier is paramount. It is a key component of the PCV regimen, where it is combined with two other agents that also have good CNS penetration: Lomustine (CCNU), a nitrosourea, and Vincristine.[1] This regimen has been a standard of care for certain types of gliomas, particularly anaplastic oligodendrogliomas with specific genetic markers.

Dosage and Administration

The dosing of Procarbazine must be meticulously managed and individualized according to the specific treatment protocol, patient response, and observed toxicities.[17]

General Dosing Principles

A critical aspect of Procarbazine dosing is the metric used, which varies by protocol and can be a source of significant medication errors if not carefully observed. Older, single-agent protocols often specify dosing based on the patient's body weight in milligrams per kilogram (mg/kg).[17] In contrast, modern combination chemotherapy regimens like MOPP and BEACOPP almost universally use body surface area (BSA) in milligrams per meter squared (mg/m²).[30] Clinicians must verify the correct metric for the specific regimen being administered. When weight-based dosing is used, it is recommended to calculate the dose based on the patient's ideal or lean body weight if the patient is obese or has significant fluid retention.[17]

Adult Dosing

• As a Single Agent: To improve gastrointestinal tolerance, therapy is often initiated with a gradual dose escalation. A typical starting dose is 2 to 4 mg/kg/day, given in single or divided doses, for the first week.[20] The dose is then increased to a therapeutic level of 4 to 6 mg/kg/day until a maximum response is achieved or dose-limiting toxicity occurs. Once a response is established, the dose is often reduced to a maintenance level of 1 to 2 mg/kg/day.[30]
• In Combination Regimens: The dose is regimen-specific. For example:
• MOPP Regimen: 100 mg/m²/day orally on days 1 through 14 of a 28-day cycle.[17]
• BEACOPP Regimen: 100 mg/m²/day orally on days 1 through 7 of a 21-day cycle.[35]

Pediatric Dosing

For pediatric patients, dosing is generally based on BSA to minimize toxicity. A recommended guideline is to start with 50 mg/m²/day for the first week. The dose is then increased to 100 mg/m²/day until a response is seen or toxicity intervenes, after which a maintenance dose of 50 mg/m²/day may be used.[30]

Dosage Modification for Toxicity

Close monitoring and prompt dose adjustments are essential for managing Procarbazine's toxicities.

• Hematologic Toxicity: This is the most common reason for dose modification. Therapy should be interrupted or suspended if:
• Leukocyte (WBC) count falls below 4,000/mm³ (some protocols use a threshold of 3,000/mm³).[17]
• Platelet count falls below 100,000/mm³ (some protocols use a threshold of 80,000/mm³).[17]
• Therapy should be discontinued permanently if any signs of hemorrhage or significant bleeding tendencies develop.[17]
• Renal and Hepatic Impairment: Procarbazine should be used with caution in patients with pre-existing kidney or liver disease, as impairment can increase drug exposure and toxicity.[3] While specific dose-reduction guidelines are not firmly established, dose adjustments are often necessary. Use is generally not recommended in patients with severe pre-existing impairment.[3]
• Other Toxicities: Therapy should be discontinued for the onset of significant neurotoxicity (e.g., paresthesia, confusion), stomatitis, or persistent diarrhea.[17]

Administration

Procarbazine is administered orally in capsule form.[3] Patients should be instructed to swallow the capsules whole with a glass of water and to not crush, chew, or open them, as this can increase exposure risk.[39] The medication can be taken with or without food; however, taking it with food or fluids, or giving the total daily dose in divided portions, may help to minimize the common side effects of nausea and vomiting.[39] Patients and caregivers should be educated on the procedures for safe handling of oral chemotherapy agents and the disposal of waste and body fluids.[19]

Safety Profile and Toxicology

The use of Procarbazine is associated with a wide range of significant toxicities, necessitating careful patient selection, intensive monitoring, and proactive management.

Boxed Warning

The FDA label for Procarbazine includes a boxed warning, the agency's strongest safety alert, which states:

"It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.".12

Adverse Drug Reactions

The adverse effects of Procarbazine are numerous and can affect nearly every organ system. A summary of notable reactions is provided in Table 4.

Table 4: Selected Adverse Drug Reactions to Procarbazine by System Organ Class

System Organ Class	Adverse Reaction	Frequency
Hematologic	Myelosuppression (Leukopenia, Thrombocytopenia, Anemia)	Very Common (>10%)
	Pancytopenia, Hemolytic anemia, Eosinophilia, Bleeding tendencies	Less Common / Rare
Gastrointestinal	Nausea and Vomiting	Very Common (>10%, up to 90%)
	Loss of appetite, Diarrhea, Constipation, Dry mouth	Common
	Stomatitis, Abdominal pain, Jaundice, Hematemesis, Melena	Less Common / Rare
Neurologic	Drowsiness, Dizziness, Lethargy, Headache, Insomnia, Nightmares	Common
	Peripheral neuropathy (paresthesias), Confusion, Hallucinations, Ataxia, Depression	Less Common
	Seizures, Coma, Nystagmus, Diminished reflexes	Rare
Dermatologic	Rash, Pruritus, Alopecia (temporary hair loss), Hyperpigmentation	Common / Less Common
Respiratory	Cough, Pneumonitis, Pleural effusion	Less Common / Rare
Cardiovascular	Hypotension, Tachycardia	Less Common / Rare
Hypersensitivity	Generalized allergic reactions, Photosensitivity	Rare
Long-Term	Secondary Malignancies (e.g., AML, lung cancer)	Rare but significant
	Infertility (Azoospermia, Ovarian failure)	Common (in specific populations)
	Teratogenicity	Established risk

Frequencies are estimated from multiple sources and may vary by regimen and patient population. Sources: [2]

Discussion of Major Toxicities

• Myelosuppression: Bone marrow suppression is the principal and most common dose-limiting toxicity of Procarbazine.[1] Leukopenia, thrombocytopenia, and anemia occur frequently. The nadir of blood counts is often delayed, typically occurring 2 to 8 weeks after the initiation of therapy, requiring monitoring to continue well after a cycle is completed.[17] Severe myelosuppression can lead to life-threatening infections or hemorrhage.
• Gastrointestinal Toxicity: Nausea and vomiting are extremely common, affecting up to 90% of patients, and can be severe.[2] These symptoms often diminish with continued treatment but may require aggressive antiemetic prophylaxis. Stomatitis, diarrhea, and constipation are also frequently reported.[14]
• Neurotoxicity: The ability of Procarbazine to readily cross the blood-brain barrier is responsible for its efficacy in brain tumors but also for its broad spectrum of neurologic side effects. These range from common and manageable symptoms like drowsiness, dizziness, and sleep disturbances to severe, dose-limiting toxicities.[19] More serious CNS effects include confusion, vivid hallucinations, depression, ataxia, and in rare cases, seizures and coma.[8] Additionally, Procarbazine can cause a progressive and often irreversible chemotherapy-induced peripheral neuropathy, manifesting as tingling, numbness, and pain in the hands and feet.[3] Any new neurologic symptom in a patient receiving Procarbazine warrants immediate and careful evaluation.
• The Triad of Irreversible Long-Term Toxicity: Beyond its acute effects, Procarbazine carries a heavy burden of profound and often permanent long-term toxicities. These risks are fundamental considerations in the decision to use the drug and demand thorough patient counseling prior to treatment.

1. Carcinogenesis: Procarbazine is a recognized human carcinogen.[13] Treatment, particularly in combination with other agents and/or radiation, significantly increases the long-term risk of developing a secondary malignancy. The most commonly reported are acute myeloid leukemia (AML) and lung cancer.[1] The risk of lung cancer is substantially multiplied in patients who use tobacco products.[13]
2. Teratogenicity: Procarbazine is designated as FDA Pregnancy Category D, indicating positive evidence of human fetal risk.[2] It is known to be teratogenic and can cause severe harm to a developing fetus. Therefore, its use during pregnancy is contraindicated unless the potential benefit in a life-threatening situation justifies the extreme risk to the fetus.
3. Impairment of Fertility: The drug has devastating effects on gonadal function, frequently causing permanent infertility in both men and women.[2] In males, it can lead to severe germ cell damage resulting in azoospermia (absence of sperm).[1] In females, it can cause premature ovarian failure and permanent amenorrhea (cessation of menstrual periods).[2] For young patients being treated with curative intent, pre-treatment counseling on these risks and discussion of fertility preservation options, such as sperm or egg cryopreservation, are essential components of care.

Contraindications

The use of Procarbazine is strictly contraindicated in patients with:

• Known hypersensitivity to Procarbazine or any of its components.[8]
• Inadequate bone marrow reserve, as determined by bone marrow aspiration and analysis, due to the high risk of profound and life-threatening myelosuppression.[8]

Drug and Food Interactions

Procarbazine is associated with an extensive and clinically critical profile of drug and food interactions, with over 500 potential drug interactions documented.[47] These interactions are not random but are driven by three distinct pharmacological properties of the drug. Understanding these mechanisms is key to preventing adverse outcomes.

MAO Inhibition-Mediated Interactions

This is the most dangerous category of interactions, stemming directly from Procarbazine's inherent ability to inhibit monoamine oxidase (MAO).[2]

• Hypertensive Crisis: MAO is responsible for breaking down dietary amines like tyramine. When MAO is inhibited by Procarbazine, ingestion of tyramine-rich foods leads to a massive release of norepinephrine, causing a rapid and dangerous spike in blood pressure known as a hypertensive crisis.[3] Symptoms include severe headache, stiff neck, chest pain, palpitations, and can be fatal.[11] Patients must be counseled to strictly avoid high-tyramine foods for the duration of therapy and for at least two weeks after discontinuation. These foods include aged cheeses, cured or fermented meats (salami, pepperoni), pickled or smoked fish, sauerkraut, fava beans, yeast extracts, and certain alcoholic beverages (red wine, tap beer).[1] Concomitant use of sympathomimetic drugs, such as pseudoephedrine and phenylephrine found in over-the-counter cold and allergy medications, can trigger the same reaction and is contraindicated.[2]
• Serotonin Syndrome: The combination of an MAO inhibitor like Procarbazine with other drugs that increase serotonin levels can lead to serotonin syndrome, a potentially lethal condition characterized by mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. Concomitant use with drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and triptans must be avoided.[49]

Disulfiram-like Reaction

Procarbazine inhibits the enzyme aldehyde dehydrogenase, the same mechanism as the drug disulfiram, which is used to deter alcohol consumption.[2]

• Mechanism and Consequence: This inhibition prevents the normal breakdown of alcohol (ethanol). If a patient consumes alcohol, the toxic metabolite acetaldehyde accumulates in the bloodstream, causing a severe and highly unpleasant reaction. Symptoms include intense facial flushing, throbbing headache, nausea, vomiting, sweating, and hypotension.[3]
• Recommendation: Patients must be unequivocally warned to avoid all alcoholic beverages and products containing alcohol during and for a period after Procarbazine therapy.[14]

Additive CNS Depression

Procarbazine itself is a central nervous system (CNS) depressant, commonly causing drowsiness, dizziness, and lethargy.[3]

• Mechanism and Consequence: When taken with other CNS depressants, these effects are potentiated, leading to profound sedation and impaired motor skills.
• Interacting Agents: This includes alcohol, opioid analgesics, barbiturates, benzodiazepines and other sedatives, many antihistamines, and phenothiazines.[1] Patients must be cautioned about the increased risk of sedation and advised to avoid activities that require mental alertness, such as driving or operating heavy machinery, until they know how the medication affects them.[43]

A summary of these critical interactions is presented in Table 5.

Table 5: Clinically Significant Drug and Food Interactions with Procarbazine

Interacting Agent/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Tyramine-Containing Foods (Aged cheese, cured meats, red wine, etc.)	MAO Inhibition	Hypertensive Crisis (severe headache, palpitations, potentially fatal)	Strict Avoidance. Counsel patient on tyramine-free diet during and for 2 weeks after therapy.
Sympathomimetic Drugs (Pseudoephedrine, phenylephrine, etc.)	MAO Inhibition	Hypertensive Crisis	Contraindicated. Avoid all OTC cold, allergy, and diet preparations.
Serotonergic Drugs (SSRIs, SNRIs, TCAs, triptans)	MAO Inhibition	Serotonin Syndrome (confusion, agitation, hyperthermia, potentially fatal)	Contraindicated. Ensure adequate washout period before starting Procarbazine.
Alcohol (Ethanol)	Aldehyde Dehydrogenase Inhibition	Disulfiram-like Reaction (flushing, headache, nausea, vomiting, hypotension)	Strict Avoidance. Counsel patient to avoid all alcoholic beverages and products.
CNS Depressants (Opioids, benzodiazepines, barbiturates, antihistamines)	Additive CNS Depression	Profound sedation, dizziness, impaired motor function	Use with extreme caution or avoid. Warn patient about additive effects and risks of driving or operating machinery.

Sources: [1]

Regulatory and Historical Context

Regulatory History and Status

Procarbazine has a long regulatory history that reflects its established role in oncology.

• Initial FDA Approval: Procarbazine, under the brand name Matulane®, was first approved for medical use in the United States by the Food and Drug Administration (FDA) in 1969.[3] It is designated as a Reference Listed Drug (RLD), serving as the standard to which generic versions are compared for bioequivalence.[51]
• Orphan Drug Designation: Recognizing its critical role in a rare disease, the FDA granted Procarbazine an Orphan Drug Designation on August 8, 2006, for the "Treatment of malignant glioma".[15] This designation facilitates development and acknowledges its importance in this specific patient population, even though it is an off-label use.
• Global Recognition: The enduring importance of Procarbazine as a fundamental cancer therapeutic is further highlighted by its inclusion on the World Health Organization's (WHO) List of Essential Medicines, a catalog of the most effective and safe medicines needed in a health system.[3]

Historical Perspective and Legacy

The story of Procarbazine is a compelling narrative of the evolution of cancer chemotherapy. As a cornerstone of the MOPP regimen developed in the 1960s, it helped usher in the modern era of oncology by proving that a disseminated cancer could be cured with drugs.[7] This achievement fundamentally changed the prognosis for patients with advanced Hodgkin's disease and provided a conceptual blueprint for treating other cancers.

Over the decades, the role of Procarbazine has shifted. It transitioned from being a standard first-line agent in the MOPP era to being largely replaced by regimens with better long-term safety profiles, such as ABVD.[3] However, it was not relegated to obsolescence. Instead, it found a new and enduring relevance in more specialized, high-risk clinical scenarios. Its inclusion in modern, dose-intensified regimens like BEACOPP for high-risk Hodgkin's lymphoma and its continued use in the PCV regimen for malignant brain tumors demonstrate its sustained value.[3] The granting of a new orphan designation in the 21st century, more than 35 years after its initial approval, is a testament to this lasting importance.[15]

Procarbazine's legacy is that of a powerful, high-risk, and complex drug that remains indispensable for specific patient populations. It serves as a potent reminder that even in the age of targeted therapies and immunotherapies, potent cytotoxic agents with unique mechanisms of action retain a critical, albeit more niche, role in the oncologic armamentarium. Its history illustrates that in the formidable fight against cancer, the older, more powerful weapons are sometimes still the most necessary tools to achieve a cure.

Works cited

1. Procarbazine (Matulane) Procarbazine (Matulane) Procarbazine is used both for Hodgkin's and non-Hodgkin's lymphoma and in treating brain tumors - Oncology, accessed August 5, 2025, https://www.pharmacology2000.com/Oncology/oncology410.htm
2. DRUG NAME: Procarbazine - BC Cancer, accessed August 5, 2025, http://www.bccancer.bc.ca/drug-database-site/drug%20index/procarbazine_monograph_1dec2011_formatted.pdf
3. Procarbazine - Wikipedia, accessed August 5, 2025, https://en.wikipedia.org/wiki/Procarbazine
4. PROCARBAZINE (PD001685, CPTBDICYNRMXFX-UHFFFAOYSA-N) - Probes & Drugs, accessed August 5, 2025, https://www.probes-drugs.org/compound/PD001685/
5. Procarbazine - LiverTox - NCBI Bookshelf, accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548411/
6. Procarbazine | C12H19N3O | CID 4915 - PubChem, accessed August 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Procarbazine
7. History of cancer chemotherapy - Wikipedia, accessed August 5, 2025, https://en.wikipedia.org/wiki/History_of_cancer_chemotherapy
8. procarbazine | Cancer Care Ontario, accessed August 5, 2025, https://www.cancercareontario.ca/en/system/files_force/procarbazine.pdf?download=1
9. Procarbazine - Sci-Hub, accessed August 5, 2025, https://2024.sci-hub.se/6245/0976b91f79ba62ad9d2278092340006d/spivack1974.pdf
10. Showing BioInteractions for Procarbazine (DB01168) | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB01168/biointeractions
11. Procarbazine - Leukemia & Lymphoma Society, accessed August 5, 2025, https://www.lls.org/procarbazine
12. MATULANE®(procarbazine hydrochloride), accessed August 5, 2025, http://www.matulane.com/
13. MATULANE- procarbazine hydrochloride capsule - DailyMed, accessed August 5, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1aa75a3a-18c9-49e1-91a6-293d0b7da756
14. Procarbazine: MedlinePlus Drug Information, accessed August 5, 2025, https://medlineplus.gov/druginfo/meds/a682094.html
15. Search Orphan Drug Designations and Approvals - FDA, accessed August 5, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=217005
16. Procarbazine Hydrochloride | C12H20ClN3O | CID 9703 - PubChem, accessed August 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Procarbazine-Hydrochloride
17. Procarbazine Monograph for Professionals - Drugs.com, accessed August 5, 2025, https://www.drugs.com/monograph/procarbazine.html
18. [Table, CHEMICAL FORMULA AND STRUCTURE]. - LiverTox - NCBI Bookshelf, accessed August 5, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548411/table/Procarbazine.Tc/
19. PROCARBAZINE HYDROCHLORIDE - CAMEO Chemicals - NOAA, accessed August 5, 2025, https://cameochemicals.noaa.gov/chemical/20952
20. Matulane (Procarbazine): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 5, 2025, https://www.rxlist.com/matulane-drug.htm
21. BEACOPP | Cancer information | Cancer Research UK, accessed August 5, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs/beacopp
22. Procarbazine - Memorial Sloan Kettering Cancer Center, accessed August 5, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/procarbazine
23. PRODUCT MONOGRAPH PrMatulane® Procarbazine hydrochloride 50 mg Capsules USP Antineoplastic agent Leadiant Biosciences, Inc. DAT, accessed August 5, 2025, https://canada.leadiant.com/wp-content/uploads/2019/12/Matulane-Monograph-English.pdf
24. Definition of procarbazine hydrochloride - NCI Drug Dictionary, accessed August 5, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/procarbazine-hydrochloride
25. Procarbazine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 5, 2025, https://www.pediatriconcall.com/drugs/procarbazine/899
26. Procarbazine (hydrochloride) (CAS 366-70-1) - Cayman Chemical, accessed August 5, 2025, https://www.caymanchem.com/product/16133/procarbazine-(hydrochloride)
27. Procarbazine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 5, 2025, https://www.mayoclinic.org/drugs-supplements/procarbazine-oral-route/description/drg-20067874
28. Procarbazine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB01168
29. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/16951236/
30. Procarbazine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 5, 2025, https://www.drugs.com/dosage/procarbazine.html
31. Matulane Dosage Guide - Drugs.com, accessed August 5, 2025, https://www.drugs.com/dosage/matulane.html
32. Procarbazine - brand name list from Drugs.com, accessed August 5, 2025, https://www.drugs.com/ingredient/procarbazine.html
33. Procarbazine Hydrochloride - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 5, 2025, https://synapse.patsnap.com/drug/733c0aacedc9465f85109d21aa6a55a5
34. Definition of BEACOPP regimen - NCI Drug Dictionary, accessed August 5, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/beacopp-regimen
35. BEACOPP-14/EscalatedBEACOPP - Quick Reference Guide - MRSA Topical Eradication, accessed August 5, 2025, https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2018/11/BEACOPP-14-Escalated-BEACOPP.pdf
36. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/9093722/
37. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/9850026/
38. beacopp - Cancer Care Ontario, accessed August 5, 2025, https://www.cancercareontario.ca/en/drugformulary/regimens/monograph/46471
39. Matulane - Drug Summary, accessed August 5, 2025, https://www.pdr.net/drug-summary/Matulane-procarbazine-hydrochloride-2727
40. Matulane (procarbazine) dosing, indications, interactions, adverse effects, and more, accessed August 5, 2025, https://reference.medscape.com/drug/matulane-procarbazine-342101
41. ORAL CANCER TREATMENT EDUCATION, accessed August 5, 2025, http://oralchemoedsheets.com/sheets/Procarbazine_Patient_Education.pdf
42. Procarbazine - BC Cancer, accessed August 5, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Procarbazine_handout.pdf
43. Procarbazine | Macmillan Cancer Support, accessed August 5, 2025, https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/procarbazine
44. Procarbazine (Matulane) - UPMC, accessed August 5, 2025, https://dam.upmc.com/-/media/cancercenter/for-patients/documents/chemo-pdfs/procarbazine.pdf?la=en&rev=06f4b969e487457d94241ac6670318e8&hash=E25FD78BB0D0DAA82A825FF4F7BB5460
45. Matulane: Package Insert / Prescribing Information - Drugs.com, accessed August 5, 2025, https://www.drugs.com/pro/matulane.html
46. procarbazine 50 mg capsule - Kaiser Permanente, accessed August 5, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.procarbazine-50-mg-capsule.208422
47. Procarbazine Interactions Checker - Drugs.com, accessed August 5, 2025, https://www.drugs.com/drug-interactions/procarbazine.html
48. Procarbazine and Alcohol/Food Interactions - Drugs.com, accessed August 5, 2025, https://www.drugs.com/food-interactions/procarbazine.html
49. Procarbazine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 5, 2025, https://www.webmd.com/drugs/2/drug-6893/procarbazine-oral/details
50. How does the drug work? Procarbazine is one of the group medicines known as alkylating agents and they exert their effect by int, accessed August 5, 2025, https://www.kmcc.nhs.uk/s3/assets/pharmacy/procarbazine-patient-information-leaflet.pdf
51. Generic Matulane Availability - Drugs.com, accessed August 5, 2025, https://www.drugs.com/availability/generic-matulane.html